> ## Content Index
> Fetch the complete content index at: https://psychedelicmentalhealth.net/llms.txt
> Use this file to discover other available public pages before exploring further.

# Spotlight: "Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition (Oughli, et al, 2023)
- URL: https://psychedelicmentalhealth.net/spotlight-intravenous-ketamine-for-late-life-treatment-resistant-depression-a-pilot-study-of-tolerability-safety-clinical-benefits-and-effect-on-cognition-oughli-et-al-2023/
- Published: 2025-09-06T21:20:54.000Z
- Updated: 2025-09-06T21:20:54.000Z
- Description: "This pilot study suggests that repeated IV ketamine infusions are well-tolerated and are associated with improvement in depression and EF in older adults with TRD."
- Author: Michael DeMarco, PhD
- Tags: ketamine, iv ketamine, depression, older adults, geriatric, geriatric mental health, geriatric depression, ketamine therapy, ketamine assisted therapy, cognition, ketamine safety, tolerability, ketamine research, research, psychedelic research

[![](https://storage.ghost.io/c/61/a8/61a8484e-df24-47fb-903c-d012ff10c983/content/images/2025/09/image-15.png)](https://www.sciencedirect.com/science/article/abs/pii/S1064748122005735)

(2023): "IV [ketamine](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/ketamine "Learn more about ketamine from ScienceDirect's AI-generated Topic Pages") was well tolerated with no discontinuation due to [adverse effects](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/adverse-event "Learn more about adverse effects from ScienceDirect's AI-generated Topic Pages"). Depressive symptoms and cognitive performance improved, with response in depression achieved in 48% of participants"